Changes of circulating anti-A/B-antibody titers during the preparation period and after AB0-incompatible living donor kidney transplantation
https://doi.org/10.23873/2074-0506-2011-0-2-3-48-53
Abstract
Several protocols have been developed to overcome the blood group barrier in renal transplantation. In the evolution of these protocols, one of the latest steps was the combination of anti-CD20 treatment with antigen-specific immunoadsorption (IA) and intravenous immunoglobulin (IvIg). This protocol has been widespread used for AB0-incompatible transplantation in Europe. We report our first experience of five successful AB0-incompatible kidney transplantation using anti-CD20 + IA + IvIg pretransplant conditioning protocol and tacrolimus + MMF + steroids as maintenance immunosuppression. Initial anti-A/B-antidody titers were 1:16 to 1:1024. The transplantation could be performed in all cases and the grafts showed primary function.
About the Authors
A. I. Sushkov
Academician V. I. Shumakov Federal Research Center of Transplantology and Artificial Organs
Russian Federation
Russian Federation
Ya. G. Moisyuk
Academician V. I. Shumakov Federal Research Center of Transplantology and Artificial Organs
Russian Federation
Russian Federation
References
1. Beimler J., Zeier M. AB0-incompatible transplantation – a safe way to perform renal transplantation? Nephrol Dial Transplant 2007;22(1):25–7.
2. Lipshutz G.S., McGuire S., Zhu Q. et al. AB0 blood type-incompatible kidney transplantation and access to organs. Arch Surg 2011;146(4):453–8.
3. Ishida H., Tanabe K., Toma H. et al. Therapeutic apheresis therapy for AB0- incompatible renal transplantations. Ther Apher Dial 2003;7(6):520–28.
4. Higgins R., Lowe D., Hathaway M. et al. Double filtration plasmapheresis in antibodyincompatible kidney transplantation. Ther Apher Dial 2010;14(4):392–9.
5. Sonnenday C.J., Warren D.S., Cooper M. et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow AB0- incompatible renal transplantation without splenectomy. Am J Transplant 2004;4(8):1315–22.
6. Tyden G., Kumlien G., Genberg H. et al. The Stockholm experience with AB0-incompatible kidney transplantations without splenectomy. Xenotransplantation 2006;13(2):105–7.
7. Tanabe K., Ishida H., Shimizu T. et al. Evaluation of two different preconditioning regimens for AB0-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated nonsplenectomy preconditioning regimens. Contrib Nephrol 2009;162:61–74.
8. Genberg H., Kumlien G., Wennberg L. et al. AB0-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008;85(12):1745–54.
9. Fuchinoue S., Ishii Y., Sawada T. et al. The 5-year outcome of AB0-incompatible kidney transplantation with rituximab induction. Transplantation 2011; 91(8):853–7.
10. Шаршаткин А.В. Клинические и хирургические аспекты трансплантации почки от живого родственного донора. Дис. … д-ра мед наук. М., 2009.
11. Kobayashi T., Saito K. A series of surveys on assay for anti-A/B antibody by Japanese AB0-incompatible Transplantation Committee. Xenotransplantation 2006; 13(2):136–40.
12. Приказ МЗ РФ № 2 от 09.01.1998 г.
13. Минеева Н.В. Группы крови человека. Основы иммуногематологии. СПб., 2005.
14. Genberg H., Kumlien G., Wennberg L., Tyden G. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in AB0-incompatible kidney transplantation. Nephrol Dial Transplant 2011;26(7):2394–400.
15. Geyer M., Fischer K.G., Drognitz O. et al. AB0-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab-insights and uncertainties. Contrib Nephrol 2009;162:47–60.
16. Norden G., Briggs D., Cockwell P. et al. AB0-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Xenotransplantation 2006;13(2):148–53.
17. Ephrem A., Misra N., Hassan G. et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med 2005;5(4):135–40.
18. Jordan S.C., Tyan D., Stablein D. et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15(12):3256–62.
Review
For citations:
Sushkov A.I., Moisyuk Ya.G. Changes of circulating anti-A/B-antibody titers during the preparation period and after AB0-incompatible living donor kidney transplantation. Transplantologiya. The Russian Journal of Transplantation. 2011;(2-3):48-53. (In Russ.) https://doi.org/10.23873/2074-0506-2011-0-2-3-48-53
Views:
658
Email this article 